CORT earnings call for the period ending December 31, 2019.
News & Analysis: Corcept Therapeutics
The company's fight to keep generic competition at bay took a turn for the worse.
The stock ricocheted around, but ultimately posted a monthly gain.
The company announced preliminary full-year 2018 results that fell below Wall Street's expectations.
An investigative report is shining light on some very serious questions about the company. Shareholders absolutely must read it.
It looks like generic versions of the company's Cushing syndrome treatment will hit a roadblock.
Solid revenue growth and pipeline progress from the biotech fueled the rise.
The pharma company announced second-quarter 2018 earnings results and lowered full-year 2018 revenue guidance.
Corcept's share price took a big hit following news that its core product may face generic competition sooner than anticipated.
Corcept Therapeutics stock posted big gains in January, but the cause for celebration proved to be short lived.
Corcept's flagship drug could be facing generic competition far sooner than expected.